Ovagen 20mg

Research buyers comparing Ovagen should review compound identity, analytical testing, COA records, lot traceability, and research-only labeling. Evaluate the product record as a laboratory material, not as a product for human, animal, clinical, therapeutic, wellness, cosmetic, or personal use.

• Ovagen is discussed here in relation to the Glu-Asp-Leu, or EDL, peptide identity; ChEBI lists Glu-Asp-Leu as a tripeptide with formula C15H25N3O8 and average mass 375.378 [1].
• Researchers evaluating an Ovagen peptide listing should compare the compound name, amino acid sequence, molecular formula, molecular weight, lot number, and COA fields across documents.
• Liver and gastrointestinal research includes hepatic and epithelial models. Interpret the findings within their in vitro systems and study limitations [8] [9].
• Published short peptide literature can inform research context, but it does not establish product-use guidance for research-use-only materials [5] [6].
• Certificates of analysis, HPLC records, LC-MS records, and mass spectrometry data help research buyers evaluate identity, purity, and batch-specific documentation [11] [12].
• A 20mg catalog reference, where present, should be treated only as a listing specification, not as a research direction or product-use quantity.

Fast Answer: What Should Researchers Check Before They Buy Ovagen for Research?

Researchers should buy Ovagen for research only after reviewing RUO labeling, compound identity, batch-specific COA documentation, purity testing, LC-MS or comparable identity verification, lot traceability, and storage records. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption.

What Documentation Should Come First?

The first documents to review are the product listing, the certificate of analysis, and any batch-specific analytical records. For peptide research materials, HPLC is commonly used to separate and evaluate peptide purity, while LC-MS and mass spectrometry can support identity and impurity characterization [11] [12].

A strong documentation set should show the same compound name, sequence identity, lot number, and test record across the listing, label, COA, and batch file. If those elements do not align, the record should be clarified before procurement.

Why Does RUO Labeling Matter Before Procurement?

RUO labeling identifies the intended research scope. FDA guidance for RUO and IUO in vitro diagnostic products ties RUO labeling to research-phase context and intended research use [20].

Ovagen Peptide Identity and Bioregulator Classification

Ovagen is discussed here in relation to Glu-Asp-Leu, abbreviated EDL, which ChEBI classifies as a tripeptide [1].

What Is Ovagen in Research Literature?

Ovagen is associated here with the Glu-Asp-Leu identity. PubChem indexes glutamyl-aspartyl-leucine as CID 444128 with molecular formula C15H25N3O8 [2].

Compare sequence, formula, molar mass, analytical test records, and batch-specific documentation.

Peptide Bioregulator Terminology for Product Documentation

Peptide bioregulator is a research classification, not evidence of product outcomes. Published short-peptide literature from Khavinson and collaborators examines DNA–peptide interactions, gene-expression models, and molecular simulations [5] [6].

That literature provides background, not evidence of outcomes for a supplied RUO material.

Amino Acid Sequence and Tripeptide Identity Signals

Glu-Asp-Leu is also written EDL. ChEBI gives the IUPAC name L-alpha-glutamyl-L-alpha-aspartyl-L-leucine and lists E-D-L and EDL as synonyms [1].

Sequence review is important because short peptides with 3 amino acids can be difficult to distinguish by product name alone. Researchers should compare the amino acid sequence, formula, and mass across the product listing, COA, and any analytical reports.

What Does Liver and Gastrointestinal Tract Research Context Include?

Hepatic models, intestinal epithelial models, cellular signaling, metabolism-related assays, and tissue-model limitations are distinct research topics. They do not establish product-use outcomes.

In vitro liver models are used to study isolated organ components under controlled, reproducible conditions, and liver model literature discusses hepatocytes, biliary epithelial cells, immune cells, and metabolic readouts [8]. Intestinal model literature likewise covers epithelial barrier models, 2D and 3D systems, and microphysiological systems used in controlled research settings [9] [10].

Liver and Gastrointestinal Model Scope

Relevant research categories include hepatic tissue, epithelial cells, and gastrointestinal model systems.

How Are Liver and Gastrointestinal Models Evaluated?

Researchers examine markers, pathways, expression data, and experimental parameters in liver and gastrointestinal models. Liver in vitro literature highlights controlled variables, organotypic characteristics, and model limitations [8].

Scientific Background for Short Peptides and Tripeptide Research

Short peptide research includes chemical identity, sequence recognition, molecular interaction models, and analytical characterization. Khavinson’s 2016 paper describes short peptides as signal-molecule models and discusses DNA-peptide complex modeling, while also stating that the molecular mechanism remains unclear [5].

That uncertainty is important.

Vladimir Khavinson and Bioregulator Literature Context

Vladimir Khavinson appears frequently in short peptide and bioregulator literature. A systematic review by Khavinson and coauthors discusses peptide regulation of gene expression and describes short peptides of 2–7 amino acid residues in gene-expression research contexts [6].

Molecular Weight, Molar Mass, and Sequence Verification

Molecular weight and molar mass support documentation review because they give researchers a fixed identity field to compare across databases, COAs, and analytical records. ChEBI lists Glu-Asp-Leu with an average mass of 375.378 and monoisotopic mass of 375.16416 [1].

Sequence verification should be tied to analytical evidence. A COA that reports purity without identity support is less complete than a record that includes both purity and identity verification.

How Does Published Literature Frame Ovagen Research?

The NCBI MMDB record 1A30 identifies a crystal structure of HIV-1 protease complexed with a tripeptide listed as Glu-asp-leu [3].

That structural context is not an RUO product claim. It is an example of how the same peptide sequence can appear in scientific databases and model-specific research.

What Published Findings Can and Cannot Support?

Published literature can support claims about what researchers studied, what methods were used, and what model-specific findings were reported. Velazquez-Campoy and colleagues reported thermodynamic binding work involving Glu-Asp-Leu and HIV-1 protease in a structure-informed research context [4].

These studies do not establish consumer suitability or outcomes for a supplied research-only product.

Research Literature and Supplier Documentation

Literature describes research questions; supplier documentation describes the listed material and its tested batch.

A peer-reviewed paper, database entry, or analytical-method source provides scientific background. It does not establish clinical, therapeutic, or consumer suitability of an RUO material.

Evidence Interpretation for Laboratory and Research Teams

Compare database identity, analytical chemistry, in vitro or structural models, preclinical studies, and literature outside RUO product use as separate evidence categories. Each answers different questions.

Source Quality Filters for Research Compounds

A practical source filter starts with official databases, peer-reviewed literature, analytical chemistry sources, and official regulatory or standards documents. PubChem, ChEBI, NCBI, FDA, USP, and peer-reviewed journals are stronger sources than vendor descriptions or unsourced marketing pages [1] [2] [16] [22].

Marketing-style claims should not be used as evidence.

How Does Experimental Design Shape Interpretation?

Experimental design determines what a study can and cannot show. In vitro models are built to control variables and isolate model components, but they also have limitations in how closely they represent more complex biology [8] [9].

Why Pathway Relevance Is Not a Product Claim?

Pathway relevance only means a pathway, model, or literature category may be relevant to research interpretation. It does not mean the product produces a particular biological outcome.

COA Review for Ovagen Peptide Documentation

A COA is one of the most important records for research procurement. It should connect a specific lot to identity, purity, analytical method, date, and laboratory source.

FDA analytical-method guidance describes validation principles for analytical procedures, including assay, purity, impurity, identity, and other qualitative or quantitative measurements [16]. That makes method clarity central to peptide documentation review.

Where Certificates of Analysis Fit in RUO Procurement?

Certificates of analysis fit between product listing review and procurement approval. They help research buyers verify whether the product’s identity and purity claims are supported by batch-specific analytical records.

USP reference standards are used to demonstrate identity, purity, and quality in compendial contexts, which supports the broader principle that reference materials and analytical records should be well characterized [22]. For RUO materials, a COA should not be treated as marketing copy; it is a technical record.

What COA Fields Should Research Buyers Compare?

Research buyers should compare compound name, lot number, COA date, test method, reported purity, identity method, observed mass where available, and issuing laboratory. FDA guidance on analytical procedures and validation emphasizes method suitability, specificity, accuracy, precision, and documented analytical performance [16] [17].

COA records are strongest when they are batch-specific. A generic COA cannot provide the same traceability as a lot-matched report.

Batch-Specific Identity and Purity Documentation

Batch-specific documentation links the tested material to the research material listing. FDA Q3A impurity guidance for new drug substances describes batch reports as including batch identity, manufacturing date, impurity content, and references to analytical procedures, which is useful as a general documentation principle [18].

For an Ovagen peptide vial, the practical question is whether the label, COA, and analytical file describe the same lot. If they do not, the documentation chain is incomplete.

Analytical Testing and Verified Purity Signals

Verified purity is not just a percentage. It depends on method, sample, batch, chromatographic conditions, and whether identity testing supports the same material record.

HPLC can help evaluate peptide purity by separating peptide components, while LC-MS can support identity and impurity characterization through mass-based analysis [11] [12]. These methods are complementary, not interchangeable.

Use this workflow to review the analytical documentation:

1. Verify that the compound name, lot number, and label match across the product page, peptide vial, COA, and batch file.
2. Review the batch-specific COA before procurement approval.
3. Check whether the purity testing method is listed, including HPLC where available [11].
4. Confirm whether identity testing is supported by LC-MS, MS, or another suitable analytical method [12] [13] [14].
5. Review chromatogram or mass data when available.
6. Check the COA date, issuing laboratory, and report clarity.
7. Document storage and handling requirements in a laboratory record, since peptide stability can be affected by intrinsic and external factors [24] [25].

How HPLC Supports Peptide Purity Review?

HPLC supports peptide purity review by separating components and producing chromatographic records that can show the main peak and related impurities under defined method conditions. Mant and colleagues describe major HPLC modes used for peptide analysis and purification, including reversed-phase, ion-exchange, and size-exclusion approaches [11].

For product-page documentation, the key issue is not simply whether “HPLC” appears. The COA should show enough method context to help a laboratory team understand what the reported purity value represents.

How LC-MS Supports Identity Verification?

LC-MS supports identity verification by pairing liquid chromatography with mass spectrometry. In peptide analysis, LC-MS workflows can help characterize synthetic peptide impurities and support molecular identity review [12] [13].

For Ovagen, LC-MS is most useful when it is tied to the lot being evaluated. A mass record that does not match the lot record is less useful for procurement review.

Mass Spectrometry Signals for Structural Integrity

Mass spectrometry can help evaluate peptide authenticity and integrity when the expected sequence and molecular mass are known. Prabhala and colleagues describe MS as well suited for identity and purity analysis of synthetic peptides [14].

Structural integrity still requires careful interpretation. A mass match can support identity review, but it should be considered alongside chromatographic data, sequence expectations, COA fields, and batch records.

Lot Traceability and Batch-Specific Documentation

Lot traceability helps laboratory teams connect the physical research material to records. FDA describes a traceability lot code as a descriptor, often alphanumeric, used to uniquely identify a traceability lot within records [21].

For peptide procurement, the same recordkeeping principle is useful. The lot number should connect the peptide vial, COA, product-page documentation, and internal laboratory record.

Why Lot Numbers Matter for Research Materials?

Lot numbers matter because research reproducibility depends on knowing which material was evaluated. A lot-specific record allows teams to connect observations, storage conditions, and analytical documentation to the same batch.

Without lot alignment, research teams may be comparing a product listing to a record that belongs to a different material. That weakens the documentation chain.

How COAs Connect to Batch Records?

COAs connect to batch records through lot number, product identity, test method, test date, and reported results. USP’s general notices emphasize identity, strength, quality, and purity in compendial contexts, supporting the wider documentation principle that material attributes need clear standards and records [23].

Labeling, Storage, and Peptide Vial Documentation

Labeling and storage records keep the research material identifiable after procurement. The peptide vial label should support the same identity chain as the product page and COA.

Storage documentation also matters because peptide stability depends on sequence, formulation, moisture, temperature, and other handling variables. Reviews of peptide stability describe intrinsic and external factors that can influence physical stability and degradation behavior [24].

What a Peptide Vial Label Should Confirm?

Compare the vial label’s compound name, lot number, catalog reference, research-only designation, and quantity against the supporting documents.

The label should also avoid claims. For a research compound, the label is part of the documentation chain, not an outcome statement.

Freeze-Drying, Lyophilized Peptide Form, and Handling Records

A lyophilized peptide form can support storage documentation because freeze drying is commonly used to improve stability of sensitive biological and pharmaceutical materials, though stability still depends on formulation and storage conditions [26].

For Ovagen documentation, “lyophilized” should be treated as a material-form descriptor. It should be paired with storage records, COA details, and laboratory handling documentation.

Key distinctions for research procurement:

• Published literature does not equal product-use guidance.
• A purity percentage does not prove complete compound identity.
• A COA should be batch-specific, not generic.
• Pathway relevance does not equal a product claim.
• Catalog sizes are listing specifications, not research directions.

Research Context and Product Evidence

Research context describes what a model examines; it does not establish an effect for a supplied product.

Research Procurement Checklist Before Researchers Buy Ovagen for Research

Before buying Ovagen for research, confirm that identity, COA, analytical records, lot number, and research-only label all describe the same material.

A practical checklist:

• Verify that the listing identifies the material as research-use-only.
• Review the batch-specific certificate of analysis.
• Confirm that purity data are supported by analytical testing.
• Check that the lot number on the COA matches the product documentation.
• Compare the compound name, molecular weight, and amino acid sequence across records.
• Assess whether the page avoids unsupported clinical, therapeutic, or consumer outcome claims.
• Document storage and handling conditions in a laboratory record.

What Should Teams Compare Before They Buy Ovagen for Research?

Teams should compare the listing, label, COA, analytical report, and supplier documentation. FDA and ICH analytical guidance emphasizes that analytical procedures should be scientifically justified and validated according to their purpose, which supports careful review of method claims [16] [17].

For a high-purity peptide listing, the record should not rely on a claim alone. It should provide method-based documentation.

How Verified Purity Supports Procurement Review?

Verified purity supports procurement review when the percentage is tied to a method and a lot. HPLC can support purity review, while LC-MS or MS can support identity review [11] [12] [14].

The strongest procurement decision is documentation-based. Purity, identity, lot traceability, and RUO labeling should all align.

Next Steps for Documentation Review

Documentation Review Path for Next-Step Evaluation

The next-step evaluation path is straightforward: verify identity, review COA records, compare analytical methods, confirm lot traceability, and check RUO labeling. If related products are reviewed, apply the same standard to each page.

Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.

Review the product-page documentation, COA details, and RUO labeling before evaluating this compound for laboratory research.

FAQs

What does research use only mean for Ovagen?

Research use only means Ovagen is intended solely for laboratory research contexts. It is not designed for human or animal consumption, diagnostic purposes, or therapeutic applications. Researchers should focus on compound identity, analytical testing, and documentation rather than any application outside controlled laboratory evaluation.

What should researchers consider before they buy Ovagen for research?

Researchers should evaluate Ovagen documentation, including batch-specific certificates of analysis (COAs), lot traceability, and analytical testing results. Reviewing HPLC or LC-MS data ensures peptide identity and purity align with research objectives. Procurement decisions should rely on these documentation standards rather than any intended-use or consumer-focused claims.

Why do researchers review COAs for Ovagen?

Researchers review COAs for Ovagen to confirm batch-specific documentation of peptide identity, purity, and analytical testing. COAs provide transparency regarding lot traceability and verify that the product meets research-use-only standards. This ensures consistent laboratory-grade material across experimental models.

What analytical methods are used to evaluate Ovagen purity?

Analytical methods such as HPLC and LC-MS are commonly applied to evaluate Ovagen purity. HPLC helps assess peptide composition and homogeneity, while LC-MS supports identity confirmation through molecular weight and mass-to-charge ratio analysis. These methods are central to RUO verification processes and documentation review.

How should published literature be interpreted for RUO Ovagen materials?

Published literature should be interpreted as research context only and not as product-use guidance. Studies describing Ovagen or similar peptides may reference in vitro assays or preclinical models. Findings should remain separate from laboratory procurement and compound documentation, maintaining RUO boundaries.

Researchers Cited in This Guide

The researchers listed below are cited for relevant published work. Their inclusion does not imply that they wrote, reviewed, or endorsed this guide or Pure Lab Peptides products.

Vladimir Khatskelevich Khavinson

Author profile: PubMed Author Profile
Vladimir Khavinson is a research author whose work appears in multiple peer‑reviewed publications examining short peptides, epigenetic regulation, and gene expression modulation. His publications provide foundational context for understanding how short peptides can interact with molecular targets and influence signaling and expression pathways in controlled laboratory settings. While the precise mechanisms remain an active area of investigation, his studies contribute to the broader literature on peptide regulation of gene expression and cellular processes.

Selected publications:

• Peptide Regulation of Gene Expression: A Systematic Review – Molecules, 2021. DOI: 10.3390/molecules26227053.
• Short Peptides Regulate Gene Expression – Bull. Exp. Biol. Med., 2016. DOI: 10.1007/s10517-016-3596-7.

Colin T. Mant

Author profile: PubMed Author Profile

Colin T. Mant’s publications examine chromatographic separation and peptide characterization. His work on HPLC methods and peptide analysis provides background for laboratory validation, purity assessment, and quality documentation.

Selected publications:

• Analysis of peptides by high-performance liquid chromatography – Methods Enzymol., 1996. DOI: 10.1016/s0076-6879(96)71003-0.
• Hydrophilic interaction/cation-exchange chromatography for separation of amphipathic alpha-helical peptides – J. Chromatogr. A., 1998. DOI: 10.1016/s0021-9673(98)00507-x.

REFERENCES

1. EMBL-EBI ChEBI. Glu-Asp-Leu CHEBI:137252. Chemical Entities of Biological Interest. Last modified 2017.
2. NIH PubChem. Glutamyl-aspartyl-leucine CID 444128. PubChem Compound Database. Accessed 2026.
3. NCBI MMDB. 1A30: HIV-1 Protease Complexed With a Tripeptide Inhibitor. Molecular Modeling Database. Updated 2021.
4. Velazquez-Campoy A, Todd MJ, Freire E. HIV-1 protease inhibitors: enthalpic versus entropic optimization of binding affinity. Biochemistry. 2000. PMID: 10694385.
5. Khavinson VK, Lin’kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bulletin of Experimental Biology and Medicine. 2016. DOI: 10.1007/s10517-016-3596-7.
6. Khavinson VK, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021. DOI: 10.3390/molecules26227053.
7. Ilina A, et al. Neuroepigenetic mechanisms of action of ultrashort peptides. International Journal of Molecular Sciences. 2022.
8. Collins SD, Yuen G, Tu T, et al. In vitro liver model overview. NCBI Bookshelf. 2019.
9. Fedi A, Vitale C, Ponschin G, et al. In vitro models replicating intestinal epithelium for research screening. Journal of Controlled Release. 2021.
10. Costa J, Ahluwalia A. Advances and current challenges in intestinal in vitro models. Frontiers in Bioengineering and Biotechnology. 2019.
11. Mant CT, Chen Y, Hodges RS. HPLC Analysis and Purification of Peptides. Methods in Molecular Biology. 2007.
12. Lian Z, et al. LC-MS characterization of synthetic peptide materials. Journal of the American Society for Mass Spectrometry. 2021. PMID: 34110145.
13. Zeng K, et al. LC-HRMS characterization of peptide materials and related impurities. Journal of Pharmaceutical and Biomedical Analysis. 2015.
14. Prabhala BK, et al. Characterization of Synthetic Peptides by Mass Spectrometry. Methods in Molecular Biology. 2015. PMID: 26424265.
15. Guzmán F, et al. Peptides, solid-phase synthesis and characterization. Electronic Journal of Biotechnology. 2023.
16. U.S. Food and Drug Administration. Q2(R2) Validation of Analytical Procedures. FDA Guidance. 2024.
17. U.S. Food and Drug Administration. Analytical Procedures and Methods Validation for Drugs and Biologics. FDA Guidance. 2015.
18. U.S. Food and Drug Administration. Q3A Impurities in New Drug Substances. FDA Guidance. 2008.
19. Electronic Code of Federal Regulations. 21 CFR 809.10: Labeling for in vitro diagnostic products. eCFR. Current as accessed 2026.
20. U.S. Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only. FDA Guidance. 2013; page current 2018.
21. U.S. Food and Drug Administration. Traceability Lot Code. FDA. 2024.
22. U.S. Pharmacopeia. USP Reference Standards. USP Official Resource. Accessed 2026.
23. U.S. Pharmacopeia. USP General Notices and Requirements. USP-NF. Accessed 2026.
24. Zapadka KL, Becher FJ, Gomes dos Santos AL, Jackson SE. Factors affecting physical stability of peptide materials. Interface Focus. 2017.
25. Tran D, et al. Comparative study of peptide storage conditions. PLoS ONE. 2012.
26. Odziomek K, et al. Freeze-drying as a stability-focused process for biological materials. Pharmaceutics. 2024.
27. National Institute of Standards and Technology. Calibration certificate evaluation checklist based on ISO/IEC 17025 reporting principles. NIST. 2019.

---

Research Disclaimer

This material is supplied strictly for in vitro laboratory research and is not for human or veterinary use. Published studies describe specific experimental materials, models, and methods; they do not establish the safety, efficacy, or suitability of this catalog product for non-research use. Review the original publications and the lot-specific analytical documentation independently.